Cormedix Inc. (CRMD) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Cormedix Inc. is a biopharmaceutical company that completed the acquisition of Melinta Therapeutics, LLC in August 2025. The financial results for Q1 2026 include the Melinta portfolio, whereas Q1 2025 results reflect only Cormedix's legacy operations (primarily DefenCath). The company operates as a single reportable segment focused on infectious disease and cardiovascular products in the United States.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $127.4 million | $39.1 million |
| Net Income | $38.6 million | $20.6 million |
| Diluted EPS | $0.43 | $0.30 |
| Gross Profit | $105.1 million | $37.5 million |
| Operating Income | $63.7 million | $20.1 million |
| Cash from Operations | $42.4 million | $19.7 million |
| Cash & Equivalents (End of Period) | $178.1 million | $66.3 million |
| Convertible Senior Notes | $144.9 million (net) | N/A |
| Contingent Consideration Liability | $105.6 million | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 226% year-over-year, driven by the inclusion of the Melinta portfolio ($24.4 million in product sales) and strong DefenCath performance ($97.5 million). A $9.0 million favorable change in accounting estimates for Medicaid rebates and product returns also boosted net sales.
- Profitability: Net income rose 87% to $38.6 million. This was supported by a 216% increase in operating income, though offset by new non-operating expenses including a $3.5 million unrealized loss on marketable securities (Talphera) and a $4.2 million increase in the fair value of contingent consideration.
- Expenses: Operating expenses increased 139% to $41.5 million due to the integration of Melinta, higher personnel costs, and increased amortization of intangible assets ($10.3 million vs. $0.1 million).
- Taxation: The company recorded a $17.0 million tax expense (30.6% effective rate) in Q1 2026, compared to zero in Q1 2025, as the company no longer maintained a full valuation allowance against deferred tax assets.
Outlook, Risks, and Management Commentary
- REZZAYO Milestone: On April 27, 2026, the company announced positive Phase III topline results for REZZAYO in the prophylaxis of invasive fungal diseases. If approved, commercialization is targeted for 2027. This success may trigger contingent consideration payments to former Melinta shareholders.
- DefenCath Reimbursement: Management expects a significant decline in DefenCath net pricing in the second half of 2026 due to the transition from TDAPA reimbursement to a post-TDAPA Add-On Adjustment by CMS. However, 2027 payment rates are estimated to increase meaningfully.
- Tariff Impact: New U.S. tariffs on imported pharmaceutical ingredients announced in April 2026 may adversely affect gross margins. The company is onshoring manufacturing to mitigate these costs.
- Capital Allocation: The company initiated a $75 million share repurchase program in February 2026 and repurchased 1.6 million shares for $11.1 million in Q1 2026.
- Internal Controls: Disclosure controls and procedures were deemed not effective as of March 31, 2026, due to a material weakness in reviewing significant non-routine transactions related to the recent acquisition and debt offering. Remediation is ongoing.
- Litigation: The company faces ongoing securities class action and derivative litigation regarding prior DefenCath manufacturing and FDA communications. A settlement term sheet was signed for the derivative litigation in December 2025, pending court approval.
Investor Verification Checklist
- Reimbursement Risk: Verify the specific impact of the CMS post-TDAPA Add-On Adjustment on DefenCath pricing in H2 2026 and the timeline for 2027 rate increases.
- Contingent Consideration: Monitor the probability and timing of the REZZAYO Second Indication approval, which could trigger up to $25 million in milestone payments plus royalties.
- Internal Control Remediation: Track the progress of remediation for the material weakness in internal controls over financial reporting to ensure future reporting reliability.
- Legal Exposure: Review the status of the securities class action litigation and the final approval of the derivative litigation settlement.
- Supply Chain: Assess the progress of onshoring manufacturing initiatives to mitigate the impact of new tariffs on APIs and excipients.